Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.73 |
| ▸ | CTSK | P43235 | 10/20 | 0.73 |
| ▸ | CTSB | P07858 | 4/20 | 0.73 |
| ▸ | CTSL | P07711 | 2/20 | 0.73 |
| ▸ | AKT1 | P31749 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279703 | 1.00 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6163314 | 1.00 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6163323 | 1.00 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL20669382 | 0.97 | CTSS (0.70) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3698861 | 0.93 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3698863 | 0.93 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6353725 | 0.91 | CTSS (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL7029483 | 0.91 | CTSS (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL22928874 | 0.91 | REN (0.71) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL7283537 | 0.89 | MMP9 (0.69) | CTSSCTSKCTSBCTSLHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021149814-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | 学校法人中部大学 | 2021-07-29 | — | — | WO | disclosed |
| EP-2872157-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2020-01-22 | — | — | EP | disclosed |
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| CN-103826661-B | Novel binding agent-drug conjugates (ADCs) and uses thereof | 西雅图基因公司 | 2019-03-05 | — | — | CN | disclosed |
| EP-3348280-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou Dac Biotech Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2017-06-08 | — | — | US | disclosed |
| CN-106117312-A | New bonding agent drug conjugate (ADC) and application thereof | 西雅图基因公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2621508-B1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | SEATTLE GENETICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2000040564-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040578-A1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040600-A1 | SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0575844-B1 | Hydroxamic acid derivatives and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0605667-A1 | DIAMINE DERIVATIVES HAVING SELECTIVE AFFINITY FOR SIGMA RECEPTORS | BATTELLE MEMORIAL INSTITUTE (CH) | 1994-07-13 | — | — | EP | disclosed |
| EP-0575844-A2 | Hydroxamic acid derivatives and pharmaceutical compositions thereof | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-29 | — | — | EP | disclosed |
| WO-1993022279-A1 | DIAMINE DERIVATIVES HAVING SELECTIVE AFFINITY FOR SIGMA RECEPTORS | BATTELLE MEMORIAL INSTITUTE (CH) | 1993-11-11 | — | — | WO | disclosed |
| US-4997950-A | Antisecretory | MURPHY RICHARD FINBAR (US) | 1991-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | CTSS 1523/4885CTSK 1843/4885CTSB 1284/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CTSS 471/4885CTSK 545/4885CTSB 1115/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | CTSS 2162/4885CTSK 1706/4885CTSB 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.